The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry
10.3346/jkms.2019.34.e185
- Author:
Ui Hong JUNG
1
;
Sang Gyu KWAK
;
Jung Yoon CHOE
;
Shin Seok LEE
;
Seong Kyu KIM
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. kimsk714@cu.ac.kr
- Publication Type:Original Article
- Keywords:
Systemic Lupus Erythematosus;
Mycophenolate Mofetil;
Non-Renal Manifestations
- MeSH:
Anemia, Hemolytic;
Arthritis;
Biomarkers;
Exanthema;
Follow-Up Studies;
Humans;
Leukopenia;
Lupus Erythematosus, Systemic;
Lupus Nephritis;
Lymphopenia;
Nervous System Diseases;
Serositis;
Surveys and Questionnaires;
Thrombocytopenia
- From:Journal of Korean Medical Science
2019;34(27):e185-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The objective of this study was to identify the effects of mycophenolate mofetil (MMF) on non-renal manifestations in systemic lupus erythematosus (SLE). METHODS: The study population comprised 439 SLE patients from the Korean Lupus Network registry who were followed up annually and completed the baseline survey and two follow-up visits from 2014 to 2018. Disease activity, laboratory markers, and clinical manifestations including mucocutaneous lesions, arthritis, serositis, neurological disorders, and hematologic/immunologic abnormalities were assessed. All variables by group (MMF and non-MMF) effects with time (baseline, 1st follow-up, and 2nd follow-up) were analyzed by generalized estimation equation. RESULTS: Seventy-two patients were treated with MMF. There was significant difference in frequencies of malar rash, arthritis, renal disorder, and hematologic disorder between MMF and non-MMF groups in total SLE patients. In subgroup analysis of hematologic abnormalities in total patients, frequency of leukopenia was significantly different between the two groups during follow-up (P = 0.001), but frequencies of hemolytic anemia, lymphopenia, and thrombocytopenia were not. In addition, frequencies of leukopenia in patients without lupus nephritis were significantly decreased in MMF group compared to non-MMF group (P = 0.012). CONCLUSION: This study showed that MMF might be a beneficial treatment for hematologic abnormalities, especially leukopenia, in SLE.
